Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a diabetes drug tame a rare heart rhythm disorder?

NCT ID NCT06174220

Disease control Sponsor: Hamilton Health Sciences Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a drug called tideglusib in 120 people with a genetic heart condition that can cause dangerous heart rhythms. The drug aims to reduce abnormal heartbeats and improve heart function. Participants will take either tideglusib or a placebo daily for about a year to see if it helps control the condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Tideglusib
What this could lead to
If successful, this could point toward a new treatment to control heart rhythm problems and slow disease progression in arrhythmogenic cardiomyopathy.
What could go wrong
This is a mid-stage trial with only 120 participants, so results may not apply to everyone. The drug may not reduce abnormal heartbeats or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * A pathogenic or likely pathogenic desmosomal (PKP2, DSG2, DSC2, DSP, or JUP\*) rare variant OR the TMEM43-p.S358L variant \*JUP carriers must be homozygous or compound heterozygous * Mean ≥ 500 PVCs per 24 hours on a baseline screening 7-day Holter monitor * Clinical ACM diagnosis or recognition of genetic carrier status for ≥ 6 months prior to screening Exclusion Criteria: * NYHA class IV heart failure * Ventricular scar secondary to coronary artery disease * Initiation, cessation, or dose change of a Class I or III anti-arrhythmic drug in the 3 months prior to screening * Any potentially harmful chronic liver disease * ALT value \> 2X the upper limit of the normal reference range at Screening * Total bilirubin value greater than the upper limit of the normal reference range at Screening, unless documented Gilbert's syndrome. For individuals with Gilbert's syndrome, total bilirubin value greater than 2-fold the upper limit of the normal reference range at Screening. * A history of alcohol or illicit substance use disorders * Regular and long-term use of strong CYP3A4 inhibitors, including clarithromycin, telithromycin, ketoconazole, itraconazole, posaconazole, nefazodone, idinavir and ritonavir * Serum creatinine \> 150 micromole/L or creatinine clearance ≤ 60 mL/min (according to Cockcroft-Gault formula) at Screening * Pregnant at time of enrollment and women of childbearing age who do not use a highly effective form of contraception * Males, engaged in sexual relations with a female of child-bearing potential, not using an acceptable contraceptive method if not surgically sterile * Patients unwilling to provide informed consent or comply with follow-up * Hypersensitivity to tideglusib or any components of its formulation, including allergy to strawberry * Concurrent use of drugs metabolized by CYP3A4 with a narrow therapeutic window e.g. warfarin and digoxin

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arrhythmogenic cardiomyopathy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Arrhythmias, Cardiac arrhythmogenic right ventricular cardiomyopathy Death, Sudden, Cardiac

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arrhythmogenic cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    17 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hamilton General Hospital

    RECRUITING

    Hamilton, Ontario, L8L 2X2, Canada

  • Heart Health Institute Research Inc

    RECRUITING

    Scarborough Village, Ontario, M1E 4B9, Canada

  • Hopital du Sacré-Coeur de Montréal

    NOT_YET_RECRUITING

    Montreal, Quebec, H4J 1C5, Canada

  • Kingston General Hospital

    NOT_YET_RECRUITING

    Kingston, Ontario, K7L 2V7, Canada

  • London Health Sciences Centre

    RECRUITING

    London, Ontario, N6A 5A5, Canada

  • McGill University Health Centre

    NOT_YET_RECRUITING

    Montreal, Quebec, H4A 3J1, Canada

  • Montreal Heart Institute

    RECRUITING

    Montreal, Quebec, H1T 1C8, Canada

  • NL Health Services

    RECRUITING

    St. John's, Newfoundland and Labrador, A1B 3V6, Canada

  • Newmarket Electrophysiologist Research Group 'NERG'

    NOT_YET_RECRUITING

    Newmarket, Ontario, L3Y 2P9, Canada

  • Nova Scotia Health

    RECRUITING

    Halifax, Nova Scotia, B3H 2Y9, Canada

  • St. Michael's Hospital

    NOT_YET_RECRUITING

    Toronto, Ontario, M5B 1W8, Canada

  • Sunnybrook Health Sciences Centre

    NOT_YET_RECRUITING

    Toronto, Ontario, M4N 3M5, Canada

  • University Institute of Cardiology and Pneumology of Quebec

    RECRUITING

    Québec, Quebec, G1V 4G5, Canada

  • University of British Columbia

    RECRUITING

    Vancouver, British Columbia, V6Z 1Y6, Canada

  • University of Calgary

    RECRUITING

    Calgary, Alberta, T2N 2T9, Canada

  • University of Ottawa Heart Institute

    NOT_YET_RECRUITING

    Ottawa, Ontario, K1Y 4W7, Canada

  • Victoria Cardiac Arrhythmia Trials Inc.

    RECRUITING

    Victoria, British Columbia, V8Z 0B9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.